INT4820

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1980
Last Reported 2007
Negated 0
Speculated 2
Reported most in Abstract
Documents 7
Total Number 9
Disease Relevance 4.06
Pain Relevance 3.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (SCT) cellular_component (SCT)
Anatomy Link Frequency
pituitary 1
SCT (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain score 4 100.00 Very High Very High Very High
Serotonin 1 100.00 Very High Very High Very High
Cholecystokinin 2 99.80 Very High Very High Very High
cINOD 3 99.58 Very High Very High Very High
Inflammation 2 99.36 Very High Very High Very High
Potency 1 96.64 Very High Very High Very High
Somatostatin 11 96.14 Very High Very High Very High
alcohol 6 95.20 Very High Very High Very High
narcan 6 89.92 High High
Morphine 6 87.52 High High
Disease Link Frequency Relevance Heat
Pain 11 100.00 Very High Very High Very High
INFLAMMATION 3 99.36 Very High Very High Very High
Sleep Disorders 62 98.32 Very High Very High Very High
Diarrhoea 7 92.08 High High
Intellectual Impairment 2 88.16 High High
Autism 44 84.04 Quite High
Osteoporosis 4 84.00 Quite High
Endometriosis (extended) 4 83.48 Quite High
Cv Unclassified Under Development 3 83.36 Quite High
Body Weight 2 81.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This study sought to determine whether cotherapy with misoprostol reverses the NSAID-induced blockade of secretin's inhibition of human gastric acid secretion.
Spec (whether) Negative_regulation (inhibition) of secretin associated with cinod
1) Confidence 0.43 Published 1995 Journal J. Clin. Gastroenterol. Section Abstract Doc Link 7769193 Disease Relevance 0.09 Pain Relevance 0.19
It would seem that the primary inhibitory effect of the elemental diet may be more specifically related to a reduction of secretin release.
Negative_regulation (reduction) of secretin
2) Confidence 0.41 Published 1980 Journal Surg Gynecol Obstet Section Abstract Doc Link 7404299 Disease Relevance 0.15 Pain Relevance 0.21
These two subjects were recruited consecutively, in a period when the data reported in literature about the potential effectiveness of secretin were promising.
Negative_regulation (effectiveness) of secretin
3) Confidence 0.41 Published 2005 Journal Clin Pract Epidemiol Ment Health Section Body Doc Link PMC1308834 Disease Relevance 0.86 Pain Relevance 0
Twenty-four women completed the trial; with i.n. sCT, the pain score decreased significantly by the second week of treatment (p < 0.05); with i.m. sCT and with placebo, the pain score decreased significantly only by the fourth week (p < 0.05), so that the final pain scores obtained with the three treatments were not different.
Negative_regulation (decreased) of sCT associated with pain score
4) Confidence 0.37 Published 1994 Journal Aging (Milano) Section Abstract Doc Link 7748920 Disease Relevance 0.96 Pain Relevance 0.76
In the secretin test, the flow rate of pancreatic juice, amylase output and bicarbonate concentration were significantly reduced as compared with the controls.
Negative_regulation (reduced) of secretin
5) Confidence 0.35 Published 1988 Journal Digestion Section Abstract Doc Link 3224767 Disease Relevance 0.64 Pain Relevance 0.47
Pancreatic secretion was stimulated with duodenal perfusion of mannitol (510 mosmol/kg) and an equimolar solution (0.3 M/liter) of L-phenylalanine and L-tryptophan and also with an intravenous bolus of secretin and cholecystokinin (each 1 CU/kg).
Negative_regulation (bolus) of secretin associated with cholecystokinin
6) Confidence 0.34 Published 1988 Journal Dig. Dis. Sci. Section Abstract Doc Link 2452060 Disease Relevance 0 Pain Relevance 0.75
The minimum region in salmon calcitonin (sCT) which induces antigenicity and gastrointestinal disturbances has been identified by examining the cross-reactivity of several sCT fragments and CT analogs with antisera from sCT-treated patients, and by examining inhibition of gastrointestinal motility of these sCT fragments and CT analogs in conscious dogs.
Spec (examining) Negative_regulation (inhibition) of sCT
7) Confidence 0.30 Published 1992 Journal Endocrinology Section Abstract Doc Link 1280207 Disease Relevance 0 Pain Relevance 0
This study found a small, non-additive reduction in performance on pharmacodynamic tests (DSST and SCT).
Negative_regulation (reduction) of SCT
8) Confidence 0.15 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656319 Disease Relevance 0.67 Pain Relevance 0.36
Octreotide has effects similar to those of somatostatin but with greater potency and longer duration of action; these effects include inhibition of pituitary release of growth hormone and thyrotropin, inhibition of glucagon or insulin release, and inhibition of the secretion of various gastrointestinal tract hormones (e.g. serotonin, pepsin, gastrin, secretin, motilin, vasoactive intestinal peptide and pancreatic peptides) [9,10].
Negative_regulation (inhibition) of secretin in pituitary associated with somatostatin, serotonin and potency
9) Confidence 0.13 Published 2005 Journal Crit Care Section Body Doc Link PMC1414034 Disease Relevance 0.68 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox